FDA Places DA01, a Cell Therapy for Advanced Parkinson’s, on Fast Track

FDA Places DA01, a Cell Therapy for Advanced Parkinson’s, on Fast Track

300068

FDA Places DA01, a Cell Therapy for Advanced Parkinson’s, on Fast Track

The U.S. Food and Drug Administration (FDA) has given fast track designation to the investigational cell therapy DA01, now in a clinical trial in people with advanced Parkinson’s disease. Developed by BlueRock Therapeutics, a wholly owned subsidiary of Bayer, DA01 is made up of dopamine-producing nerve cells derived from human embryonic stem cells. These cells are pluripotent, meaning they can generate almost any type of human cell. Transplantation of these cells aims to repopulate a patient’s brain…

You must be logged in to read/download the full post.